ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

ClinicalTrials.gov ID: NCT04508530

Public ClinicalTrials.gov record NCT04508530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Study identification

NCT ID
NCT04508530
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Octapharma
Industry
Enrollment
71 participants

Conditions and interventions

Interventions

  • Panzyga Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2021
Primary completion
Aug 26, 2024
Completion
Oct 29, 2024
Last update posted
Jan 6, 2026

2021 – 2024

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Octapharma Research Site Tucson Arizona 85712
Octapharma Research Site Little Rock Arkansas 72202
Octapharma Research Site Los Angeles California 90024
Octapharma Research Site Palo Alto California 94305
Octapharma Research Site Centennial Colorado 80112
Octapharma Research Site Boston Massachusetts 02114
Octapharma Research Site Lebanon New Hampshire 03756

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04508530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04508530 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →